Repository logo
 
Publication

Novel pharmaceutical and nutraceutical-based approaches for cardiovascular diseases prevention targeting atherogenic small dense LDL

2022-04Journal article Open access
Simple item page
dc.contributor.authorVekic, Jelena
dc.contributor.authorZeljkovic, Aleksandra
dc.contributor.authorStefanovic, Aleksandra
dc.contributor.authorBogavac-Stanojevic, Natasa
dc.contributor.authorIlias, Ioannis
dc.contributor.authorSilva-Nunes, José
dc.contributor.authorStoian, Anca Pantea
dc.contributor.authorJanez, Andrej
dc.contributor.authorRizzo, Manfredi
dc.date.accessioned2022-04-26T11:31:58Z
dc.date.available2022-04-26T11:31:58Z
dc.date.issued2022-04
dc.description.abstractCompelling evidence supports the causative link between increased levels of low-density lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular disease (CVD) development. For that reason, the principal aim of primary and secondary cardiovascular prevention is to reach and sustain recommended LDL-C goals. Although there is a considerable body of evidence that shows that lowering LDL-C levels is directly associated with CVD risk reduction, recent data shows that the majority of patients across Europe cannot achieve their LDL-C targets. In attempting to address this matter, a new overarching concept of a lipid-lowering approach, comprising of even more intensive, much earlier, and longer intervention to reduce LDL-C levels, was recently proposed for high-risk patients. Another important concern is the residual risk for recurrent cardiovascular events despite optimal LDL-C reduction, suggesting that novel lipid biomarkers should also be considered as potential therapeutic targets. Among them, small dense LDL particles (sdLDL) seem to have the most significant potential for therapeutic modulation. This paper discusses the potential of traditional and emerging lipid-lowering approaches for cardiovascular prevention by targeting sdLDL particles.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationVecik J, Zeljkovic A, Stefanovic A, Bogavac-Stanojevic N, Ilias I, Silva-Nunes J, et al. Novel pharmaceutical and nutraceutical-based approaches for cardiovascular diseases prevention targeting atherogenic small dense LDL. Pharmaceutics. 2022;14(4):825.pt_PT
dc.identifier.doi10.3390/pharmaceutics14040825pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.21/14589
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMDPIpt_PT
dc.relation.publisherversionhttps://www.mdpi.com/1999-4923/14/4/825pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectLipidspt_PT
dc.subjectLipoproteinspt_PT
dc.subjectSmall dense LDLpt_PT
dc.subjectCholesterolpt_PT
dc.subjectHealth preventionpt_PT
dc.subjectTherapypt_PT
dc.titleNovel pharmaceutical and nutraceutical-based approaches for cardiovascular diseases prevention targeting atherogenic small dense LDLpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue4pt_PT
oaire.citation.startPage825pt_PT
oaire.citation.titlePharmaceuticspt_PT
oaire.citation.volume14pt_PT
person.familyNameSilva-Nunes
person.givenNameJosé António
person.identifier.ciencia-id4B1C-E132-25F0
person.identifier.orcid0000-0002-4728-1220
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication9352b380-9661-4316-ab88-6ed9be1020ac
relation.isAuthorOfPublication.latestForDiscovery9352b380-9661-4316-ab88-6ed9be1020ac

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Novel pharmaceutical and nutraceutical-based approaches for cardiovascular diseases prevention targeting atherogenic small dense LDL.pdf
Size:
662.75 KB
Format:
Adobe Portable Document Format
Download

Collections

ESTeSL - Artigos